HK Stock Market Move | DEKON AGR(02419) rose by over 5% in the afternoon. The company has been buying back shares for 9 consecutive days, with a total buyback of approximately HK$1.25 billion so far this year.
Dekang Agriculture and Animal Husbandry (02419) surged more than 5% in the afternoon, as of the time of writing, was up 4.93% at HK$70.2, with a turnover of HK$92.8464 million.
DEKON AGR (02419) rose more than 5% in the afternoon, as of the time of publication, it had risen by 4.93% to 70.2 Hong Kong dollars with a turnover of 92.8464 million Hong Kong Dollars.
On the news side, DEKON AGR repurchased 280,300 shares on April 10, with a repurchase amount of 185.983 million Hong Kong Dollars. Data shows that the company has been conducting repurchases for 9 consecutive days since March 26, with a total repurchase of 1.1864 million shares and a cumulative repurchase amount of 77.314 million Hong Kong Dollars. So far this year, the stock has conducted 32 repurchases, repurchasing a total of 1.879 million shares with a cumulative repurchase amount of 1.25 billion Hong Kong Dollars.
It is worth noting that DEKON AGR announced that it sold 1.0059 million commodity pigs in March, with sales revenue of 1.382 billion yuan. In early April, the Ministry of Commerce, the National Development and Reform Commission, and the Ministry of Finance announced the launch of the central reserve frozen pork collection work. Earlier, the Development and Reform Commission, in conjunction with the Ministry of Agriculture and Rural Affairs, held two special meetings, requiring major breeding companies to strictly implement production capacity control measures and orderly reduce the stock of breeding sows.
Related Articles

Ping An Insurance (02318): Cai Fangfang resigns as executive director of the thirteenth board of directors.

CF PHARMTECH (02652) spent HK$366,900 on May 14 to repurchase 17,500 shares.

CHINA CINDA (01359): Wang Zhongze appointed as an independent non-executive director.
Ping An Insurance (02318): Cai Fangfang resigns as executive director of the thirteenth board of directors.

CF PHARMTECH (02652) spent HK$366,900 on May 14 to repurchase 17,500 shares.

CHINA CINDA (01359): Wang Zhongze appointed as an independent non-executive director.

RECOMMEND

Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026

HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026

The Chip Stock Frenzy Is Still Accelerating
11/05/2026


